Ingredient comparison

Orforglipron vs Tirzepatide

Last updated

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Orforglipron vs Tirzepatide: lowest prices now

  • Orforglipron: lowest FDA-approved

    LillyDirect (Eli Lilly)

    from $149/mo · about $149 per 30 days

  • Tirzepatide: lowest FDA-approved

    LillyDirect (Eli Lilly)

    $299-$449/28 days · about $320 per 30 days

  • Tirzepatide: lowest compounded on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Orforglipron vs Tirzepatide: overview
CompareOrforglipronTirzepatide
What it is for

FDA-approved for

  • Weight loss

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Sleep apnea
Brands
Foundayo

Small-molecule GLP-1

Route & frequency

Oral tablet (any time of day, no food or water restriction)

Once daily

Subcutaneous injection

Once weekly

FDA shortage report

National reporting does not confirm stock at your pharmacy.

Coverage & source records

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Orforglipron vs Tirzepatide: sourced cash quotes
CompareOrforglipronTirzepatide
Advertised entry price
$149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT)

Foundayo via Amazon Pharmacy

Amazon Pharmacy

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

Zepbound KwikPen via Amazon Pharmacy

Amazon Pharmacy

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

28-day supply (pharmacy.amazon.com)

≈ $320.36 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

At the named trial dose
$299/30 days (pharmacy.amazon.com/Eli-Lilly-FOUNDAYO-17-2-MG-TABLET-Bottle-30-Tablet/dp/B0GVPWWC4K)

Foundayo via Amazon Pharmacy

At 17.2 mg

Amazon Pharmacy

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

30-day supply (pharmacy.amazon.com)

$299 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

$449/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-15-MG-DOSE-PEN-INJ/dp/B0GP1V2X9V)

Zepbound KwikPen via Amazon Pharmacy

At 15 mg

Amazon Pharmacy

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699)

28-day supply (pharmacy.amazon.com)

≈ $481.07 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699)

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Every offerAll 51 offersAll 885 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Orforglipron vs Tirzepatide: individual trial outcomes
CompareOrforglipronTirzepatide
Weight change
−11.2% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose))

-11.2% at 72 wks

ATTAIN-1 (nejm.org)

17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)

Accounts for treatment discontinuation

Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

−20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound))

-20.9% at 72 wks

SURMOUNT-1 (nejm.org)

15 mg weekly (Zepbound)

Accounts for treatment discontinuation

Study context

SURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results.

HbA1c change (percentage points)
−1.5 pp (investor.lilly.com/node/52521) (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points)

-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1)

ACHIEVE-1 (investor.lilly.com)
−2.3 pp (investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine) (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points)

-2.3 percentage points at 40 wks

SURPASS-2 (investor.lilly.com)
Adverse events

Stopped treatment for adverse events

10.3% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))

Reported nausea

33.7% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))

ATTAIN-1 (36 mg, 72 wks, obesity)

Stopped treatment for adverse events

6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))

Reported nausea

31% (nejm.org/doi/full/10.1056/NEJMoa2206038) (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))

SURMOUNT-1 (15 mg, 72 wks, obesity)

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298
Foundayo17.2 mg from day 151about 29 to 49 hoursNoSep 26, 2037None listed

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Orforglipron

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

53 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Tirzepatide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

317 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Orforglipron or Tirzepatide better for weight loss?

No trial on our list compared them directly. In separate trials: Orforglipron -11.2% at 72 wks in ATTAIN-1 (17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)) (nejm.org); Tirzepatide -20.9% at 72 wks in SURMOUNT-1 (15 mg weekly (Zepbound)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.

Is Orforglipron or Tirzepatide safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Orforglipron 10.3% vs 2.7% placebo (36 mg) (ATTAIN-1 (36 mg, 72 wks, obesity)) (nejm.org); Tirzepatide 6.2% vs 2.6% placebo (15 mg) (SURMOUNT-1 (15 mg, 72 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Tirzepatide dose is equivalent to Orforglipron?

No FDA label sets a dose of Orforglipron that equals a dose of Tirzepatide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Orforglipron or Tirzepatide?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Orforglipron and Tirzepatide

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.